title: Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database.
abstract: OBJECTIVE
  Bullous pemphigoid has been reported in association with gliptins. We describe a case, review the literature and analyse all cases of bullous pemphigoid recorded in the European pharmacovigilance database, EudraVigilance.
  
  
  METHODS
  A 74-year-old woman, treated with vildagliptin/metformin for 12 months, developed bullous pemphigoid, confirmed by skin biopsy. The symptoms resolved within 7 months after vildagliptin/metformin withdrawal.
  
  
  CONCLUSIONS
  A search in EudraVigilance showed a disproportionality for bullous pemphigoid and gliptins, except alogliptin. These findings extend the evidence associating gliptins with this potentially serious disease.
authors.affiliation: Basque Country Pharmacovigilance Unit, Galdakao-Usansolo Hospital, Galdakao, Spain.
authors.forename: M
authors.initials: M
authors.lastname: García
authors.affiliation: Mutriku Primary Health Care, Mutriku, Spain.
authors.forename: M A
authors.initials: MA
authors.lastname: Aranburu
authors.affiliation: Pharmacy Service, Galdakao-Usansolo Hospital, Galdakao, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Palacios-Zabalza
authors.affiliation: Pharmacy Service, Araba's Mental Health Network, Vitoria-Gasteiz, Spain.
authors.forename: U
authors.initials: U
authors.lastname: Lertxundi
authors.affiliation: Basque Country Pharmacovigilance Unit, Galdakao-Usansolo Hospital, Galdakao, Spain.|Department of Pharmacology, Faculty of Medicine, University of Basque Country, Leioa, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Aguirre
keywords: adverse drug reactions; bullous pemphigoid; gliptins